Please note that IPD sharing statement and summary results sections will be added to the ANZCTR form in the coming months in order to comply with the updated WHO Trial Registration Data Set.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00009698




Trial ID
NCT00009698
Ethics application status
Date submitted
2/02/2001
Date registered
30/12/2003
Date last updated
27/06/2013

Titles & IDs
Public title
Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia
Scientific title
IL-2 Infusion in AML Patients After Autologous Bone Marrow Transplant: A Pediatric Oncology Group Wide Phase I Trial
Secondary ID [1] 0 0
POG-9674
Secondary ID [2] 0 0
9674
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Leukemia 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - aldesleukin

Experimental: All patients - Day 1 through day 7, days 9-14 and days 16-22: The assigned dose of IL-2 will be administered SQ. On days 8 and 15, IL-2 will be administered as a 2 hour intravenous infusion of one million units/M2 of IL-2. After day 22 there will be a 7 day rest period before beginning the next cycle. The next cycle will repeat just as above. This will be repeated for a maximum of 4 total cycles of 21 days of IL-2 therapy. The maintenance dose of IL-2 will always be the same as given during cycle one, unless there is dose limiting toxicity.


Other interventions: aldesleukin
Given SQ and IV

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To determine the maximum tolerated dose (MTD) of IL-2
Timepoint [1] 0 0
2 years

Eligibility
Key inclusion criteria
DISEASE CHARACTERISTICS: Diagnosis of acute myeloid leukemia (AML) Must have received
autologous bone marrow or stem cell transplantation for AML within the past 28 to 100 days
Evidence of marrow engraftment Absolute neutrophil count at least 500/mm3 for at least 2
consecutive days Platelet count at least 20,000/mm3 without transfusion support for more
than 3 days Documented M1 or M2 bone marrow within the past 7 days

PATIENT CHARACTERISTICS: Age: Under 22 at diagnosis Performance status: Karnofsky 50-100%
Life expectancy: At least 8 weeks Hematopoietic: See Disease Characteristics Hepatic:
Bilirubin no greater than 1.5 mg/dL SGPT no greater than 2 times normal Renal: Creatinine
normal OR Glomerular filtration rate at least 70 mL/min Cardiovascular: Shortening fraction
at least 27% OR Ejection fraction greater than 50% No evidence of active cardiac disease by
electrocardiogram Pulmonary: No evidence of active pulmonary disease by chest x-ray Other:
Not pregnant or nursing Negative pregnancy test Fertile patients must use effective
contraception Neurologic deficits due to CNS disease must be stable within the past 4 weeks
No active viral, bacterial, or invasive fungal infection No fever No prior hypersensitivity
to interleukin-2 No greater than grade 2 mucosal toxicity

PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 3 days
since prior growth factors or intravenous immunoglobulin No concurrent cytokines or growth
factors No concurrent intravenous immunoglobulin Chemotherapy: No concurrent chemotherapy
No concurrent methotrexate IV or intrathecally Endocrine therapy: At least 3 days since
prior corticosteroids No concurrent corticosteroids (except as premedication for documented
severe transfusion reactions) Radiotherapy: Not specified Surgery: Not specified Other: At
least 3 days since prior pentoxifylline or amphotericin B No concurrent pentoxifylline No
other concurrent anticancer therapy
Minimum age
No limit
Maximum age
21 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Royal Children's Hospital - Parkville
Recruitment postcode(s) [1] 0 0
3052 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
District of Columbia
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Hawaii
Country [10] 0 0
United States of America
State/province [10] 0 0
Illinois
Country [11] 0 0
United States of America
State/province [11] 0 0
Kansas
Country [12] 0 0
United States of America
State/province [12] 0 0
Louisiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Maine
Country [14] 0 0
United States of America
State/province [14] 0 0
Maryland
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Michigan
Country [17] 0 0
United States of America
State/province [17] 0 0
Mississippi
Country [18] 0 0
United States of America
State/province [18] 0 0
Missouri
Country [19] 0 0
United States of America
State/province [19] 0 0
New Hampshire
Country [20] 0 0
United States of America
State/province [20] 0 0
New Jersey
Country [21] 0 0
United States of America
State/province [21] 0 0
New Mexico
Country [22] 0 0
United States of America
State/province [22] 0 0
New York
Country [23] 0 0
United States of America
State/province [23] 0 0
North Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Oklahoma
Country [25] 0 0
United States of America
State/province [25] 0 0
Oregon
Country [26] 0 0
United States of America
State/province [26] 0 0
Pennsylvania
Country [27] 0 0
United States of America
State/province [27] 0 0
South Carolina
Country [28] 0 0
United States of America
State/province [28] 0 0
Tennessee
Country [29] 0 0
United States of America
State/province [29] 0 0
Texas
Country [30] 0 0
United States of America
State/province [30] 0 0
Vermont
Country [31] 0 0
United States of America
State/province [31] 0 0
Virginia
Country [32] 0 0
United States of America
State/province [32] 0 0
Washington
Country [33] 0 0
United States of America
State/province [33] 0 0
West Virginia
Country [34] 0 0
United States of America
State/province [34] 0 0
Wisconsin
Country [35] 0 0
Canada
State/province [35] 0 0
Alberta
Country [36] 0 0
Canada
State/province [36] 0 0
Ontario
Country [37] 0 0
Canada
State/province [37] 0 0
Quebec
Country [38] 0 0
Netherlands
State/province [38] 0 0
Groningen
Country [39] 0 0
Puerto Rico
State/province [39] 0 0
Santurce
Country [40] 0 0
Switzerland
State/province [40] 0 0
Bern
Country [41] 0 0
Switzerland
State/province [41] 0 0
Geneva
Country [42] 0 0
Switzerland
State/province [42] 0 0
Lausanne

Funding & Sponsors
Primary sponsor type
Other
Name
Children's Oncology Group
Address
Country
Other collaborator category [1] 0 0
Government body
Name [1] 0 0
National Cancer Institute (NCI)
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill more cancer
cells.

PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating children who
have undergone bone marrow transplantation for acute myeloid leukemia.
Trial website
https://clinicaltrials.gov/show/NCT00009698
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Kimo C. Stine, MD
Address 0 0
Arkansas Children's Hospital at the University of Arkansas for Medical Sciences
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries